In the winter of 2014–2015, a novel norovirus (NoV) strain (GII.17) was reported to be the major cause of gastroenteritis outbreaks in East Asia. To determine the time course of gastroenteritis infections associated with the GII.17 strain and whether GII.17 was the main epidemic strain in diarrheal patients in Shanghai, 2169 stool samples were collected and tested. The detection rate of NoV GI and GII NoV strains was 0.83 and 24.02%, respectively. Phylogenetic analysis confirmed that there were seven NoV genotypes, among which GII.4 and GII.17 were the main genotypes. The GII.17 strain was first detected in a sample collected on August 14th, 2014, and beginning in January 2015, the novel GII.17 strain replaced the GII.4 strain as the dominant NoV genotype causing acute gastroenteritis in patients in Shanghai.
Hinweise
Lifeng Pan and Caoyi Xue contributed equally to this work
Norovirus (NoV) is a leading cause of diarrhea inpatients of all age groups with acute gastroenteritis worldwide [1]. Starting in November 2014, Guangdong [2], Jiangsu [3], and Zhejiang [4] in China, and Japan [5] reported diarrheal disease outbreaks that were caused by a novel NoV genotype GII.17. Chen et al. [6] reported this novel genotype collected from sporadic patients in Shanghai during the winter of 2014–2015 has evolutionary relationships with other reported genotypes [2, 5]. Here, we characterized the molecular epidemiology of NoV infections in Shanghai between July 2014 and June 2015 to examine when did this novel NoV genotype strain begin to prevalent and whether the NoV GII.4 is still the leading NoV genotype in Shanghai, China.
A total of 2169 stool samples were collected from 18,669 diarrheal patients, reported to the syndromic surveillance network from 12 sentinel hospitals, between July 2014 and June 2015. The detection rate of the NoV GI and GII was 0.83% (18/2169) and 24.02% (521/2169) by real-time reverse transcription polymerase chain reaction (qRT-PCR), respectively.
Anzeige
Partial nucleotide sequences of the NoV GII ORF2 gene was amplified. Genotypes were determined using Norovirus Genotyping Tool Version 1.0. The numbers of strains corresponding to the GII.2, GII.3, GII.4, GII.6, GII.13, GII.17 and GII.21 strains were 3, 5, 133, 3, 8, 286 and 10, respectively. GII.17 (63.84%, 286/448) and GII.4 (29.69%, 133/448) were the most prevalent NoV GII genotypes between July 2014 and January 2015.
NoV infections occurred in all seasons and peaked between October 2014 and April 2015 (Fig. 1). The novel genotype GII.17 strain was first detected in a 24-year-old female patient on August 14th, 2014 in Shanghai. Beginning in January 2015, GII.17, which clustered to the novel variant Kawasaki_2014, was the most prevalent genotype of NoV GII, replacing GII.4 as the most prevalent NoV genotype in Shanghai. After May 2015, the GII.4 strain was rarely detected (Fig. 1).
×
As the most prevalent strain, the GII.4 genotype Sydney_2012 and its variants were surveyed and reported globally [7‐12], beginning in 2012 [13]. However, starting in November 2014, a novel NoV genotype GII.17 was reported to cause diarrheal disease outbreaks, worldwidely [2, 5, 14‐16] and Matesushiam et al. [5] found that this novel genotype had a polymerase sequence and amino acid substitutions in the capsid region. In this study, we reported that the GII.17 genotype was first detected in diarrheal patients in August 2014, which was earlier than the first reported outbreak in Jiangsu [3]. Similar with the findings by Chen et al. [6], the GII.17 genotype became the predominant genotype beginning in November 2014 (Fig. 2). Our findings demonstrate that beginning in December 2014, GII.17 replaced GII.4 as the most prevalent NoV genotype in Shanghai. Teasing out viral, environmental, or host specific factors should be investigated to understand emergence of GII.17 [15] and ongoing surveillance should be performed to verify whether this novel genotype would be prevalent continuously.
×
Authors’ contributions
LP and YF conceived and designed the experiments. HF, DL and LZ performed the experiments. CX and CC performed the statistical analysis. WZ, YF and QS conceived the study. LP and XY wrote the manuscript. All authors read and approved the final manuscript.
Anzeige
Acknowledgements
We thank the staff of 12 sentinel hospitals in the present study.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The database supporting the conclusions of this article is included within the article’s Additional file.
Ethics approval and consent to participate
The study protocol was in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Review Board at Shanghai Pudong New Area Center for Disease Control and Prevention.
Funding
This work was supported in part by Key Discipline Construction in Pudong New Area Health System (No.PWzx2014-14), Pudong New Area Science and Technology Development-Innovation Fund (No. PKJ2013-Y39) and Research Grant for Health Science and Technology of Pudong Health and Family Planning of Shanghai (Grant No. PW2015B-4). The funder had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.
Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.
Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.
Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.